白蛋白结合型紫杉醇诱导的基质重编程驱动胰腺癌患者新辅助化疗耐药
Albumin-bound paclitaxel–induced stromal reprogramming drives resistance to neoadjuvant chemotherapy in patients with pancreatic cancer
发表于 Science Translational Medicine 的研究显示,白蛋白结合型紫杉醇可诱导胰腺癌患者基质重编程,从而驱动对新辅助化疗的耐药。材料仅提供摘要与卷期信息,未给出样本量、对照设计与效应量。
原文摘要
出版方登记 · CrossrefPancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy for which neoadjuvant chemotherapy with albumin-bound paclitaxel combined with gemcitabine (AG) is a standard first-line approach for borderline resectable and locally advanced disease. However, secondary resistance to this regimen is common, and its underlying mechanisms remain poorly defined. In this study, we investigated how neoadjuvant AG therapy shapes the tumor stroma in PDAC. Single-cell transcriptomics of patient tumors revealed that AG treatment induces a phenotypic switch of cancer-associated fibroblasts (CAFs) from myofibroblastic (myCAF) to inflammatory (iCAF) states and identified a previously unrecognized TMEM100 + CAF subset enriched in nonresponders. Mechanistic studies showed that albumin-bound paclitaxel activates IL-2–STAT5 signaling to drive TMEM100 expression and that TMEM100 + CAFs promote chemoresistance through paracrine secretion of amphiregulin (AREG) and activation of tumor EGFR signaling. Genetic ablation of TMEM100 + CAFs in mouse models reversed CAF switching and enhanced the antitumor efficacy of AG therapy. These findings map chemotherapy-induced CAF plasticity, reveal a TMEM100-AREG axis of resistance, and highlight TMEM100 + CAFs as a promising target to sensitize PDAC to neoadjuvant treatment.
页面未能读取全文,以上为出版方登记的摘要;方法与图表见原文
来源:Science Translational Medicine · science.org